<DOC>
	<DOCNO>NCT00281528</DOCNO>
	<brief_summary>This multi-center , open-label , randomized Phase II study previously untreated patient metastatic breast cancer evaluate antitumor activity safety weekly dose-dense ABI-007 ( Abraxane ) compare 2-weekly regimen vs standard 3-weekly infusion . All patient also receive concurrent bevacizumab .</brief_summary>
	<brief_title>Weekly vs. Every 2 Week vs. Every 3 Week Administration ABI-007 ( Abraxane ) /Bevacizumab Combination Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Pathologically confirm adenocarcinoma breast . Stage IV disease Measurable disease Patients must candidate Herceptin therapy At least 4 week since radiotherapy , full recovery . The measurable disease must completely outside radiation portal must pathologic proof progressive disease within radiation portal . At least 4 week since major surgery , full recovery . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Female &gt; 18 year age . Patient follow blood count Baseline : Absolute neutrophil count ≥ 1.5 x 10^9cells/L ; platelet ≥ 100 x 10^9 cells/L ; hemoglobin ≥ 9 g/dL . Patient follow blood chemistry level Baseline : Aspartate transaminase ( AST SGOT ) , alanine aminotransferase ( ALT SGPT ) ≤ 2.5x upper limit normal range ( ULN ) ; total bilirubin ≤ ULN ; creatinine ≤ 1.5 mg/dL . If female childbearing potential , pregnancy test negative within 72 hour first dose study drug . If fertile , patient agrees use effective method avoid pregnancy duration study . Informed consent obtain . Prior neoadjuvant adjuvant chemotherapy allow , patient must recover acute toxicity therapy . No prior therapy metastatic disease allow . If taxane part adjuvant regimen , least 12 month pass completion taxane regimen relapse . If nontaxanebased adjuvant therapy administer , least 6 month pass completion relapse . Concurrent immunotherapy hormonal therapy . Parenchymal brain metastasis , include leptomeningeal involvement . Inadequately control hypertension ( define blood pressure &gt; 150/100 mmHg ) New York Heart Association ( NYHA ) Grade 2 great congestive heart failure . Any prior history hypertensive crisis hypertensive encephalopathy . History myocardial infarction unstable angina within 6 month prior study enrollment . History stroke transient ischemic attack within 6 month prior study enrollment . Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) . Symptomatic peripheral vascular disease . Evidence bleed diathesis coagulopathy . History abdominal fistula , gastrointestinal perforation , intra abdominal abscess within 6 month prior study enrollment . Proteinuria screen demonstrate either : Urine protein : creatinine ( UPC ) ratio &gt; 1.0 screening OR Urine dipstick proteinuria ≥ 2+ ( patient discover ≥ 2+ proteinuria dipstick urinalysis baseline undergo 24hour urine collection must demonstrate ≤ 1g protein 24 hour eligible ) . Known hypersensitivity component bevacizumab . Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior first dose . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior first dose , anticipation need major surgical procedure course study . Serious , nonhealing wound , ulcer , bone fracture . Serious intercurrent medical psychiatric illness , include serious active infection . History malignancy within last 5 year could affect diagnosis assessment breast cancer . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study . Pregnant nursing woman . Sensory neuropathy &gt; Grade 1 baseline .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>First Line Metastatic Breast Cancer</keyword>
</DOC>